- Home
- LINE vs VTRS Comparison
LINE vs VTRS Comparison
Compare LINE & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LINE
- VTRS
- Stock Information
- Founded
- LINE 2012
- VTRS 1961
- Country
- LINE United States
- VTRS United States
- Employees
- LINE N/A
- VTRS N/A
- Industry
- LINE
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- LINE
- VTRS Health Care
- Exchange
- LINE NYSE
- VTRS Nasdaq
- Market Cap
- LINE 13.1B
- VTRS 14.0B
- IPO Year
- LINE 2024
- VTRS N/A
- Fundamental
- Price
- LINE $58.18
- VTRS $11.30
- Analyst Decision
- LINE Buy
- VTRS Hold
- Analyst Count
- LINE 16
- VTRS 3
- Target Price
- LINE $86.56
- VTRS $13.67
- AVG Volume (30 Days)
- LINE 980.8K
- VTRS 10.3M
- Earning Date
- LINE 02-15-2025
- VTRS 02-26-2025
- Dividend Yield
- LINE 3.63%
- VTRS 4.22%
- EPS Growth
- LINE N/A
- VTRS N/A
- EPS
- LINE N/A
- VTRS N/A
- Revenue
- LINE $5,331,900,000.00
- VTRS $15,048,500,000.00
- Revenue This Year
- LINE N/A
- VTRS N/A
- Revenue Next Year
- LINE $3.94
- VTRS N/A
- P/E Ratio
- LINE N/A
- VTRS N/A
- Revenue Growth
- LINE 8.19
- VTRS N/A
- 52 Week Low
- LINE $52.75
- VTRS $9.93
- 52 Week High
- LINE $89.85
- VTRS $13.62
- Technical
- Relative Strength Index (RSI)
- LINE N/A
- VTRS 28.18
- Support Level
- LINE N/A
- VTRS $11.13
- Resistance Level
- LINE N/A
- VTRS $12.02
- Average True Range (ATR)
- LINE 0.00
- VTRS 0.32
- MACD
- LINE 0.00
- VTRS -0.09
- Stochastic Oscillator
- LINE 0.00
- VTRS 10.97
About LINE LINEAGE INC
Lineage Inc is a Real Estate Investment Trust. The company is engaged in delivering end-to-end, technology-enabled, customer experience for thousands of customers with their customizations in the temperature-controlled supply chain to eliminate wastage of food. The services provided by the company are Cold Storage Warehousing, Automated Warehousing, Port-Centric Warehousing, Sustainable Warehousing, Freight Forwarding, Drayage, Customs Brokerage, and others.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.